sorafenib has been researched along with vitamin k 1 in 7 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (vitamin k 1) | Trials (vitamin k 1) | Recent Studies (post-2010) (vitamin k 1) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,699 | 131 | 410 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Carr, BI; Wang, M; Wei, G | 1 |
| Carr, BI; Cavallini, A; D'Alessandro, R; Refolo, MG; Wang, M; Wang, Z | 1 |
| Du, W; Gong, K; Wang, DL; Zhang, QJ; Zhou, JR | 1 |
| Katare, DP; Mishra, S | 1 |
| Chen, RX; Cui, JF; Dong, G; Dong, YY; Gao, DM; Li, JH; Ma, H; Ma, M; Ren, ZG; Yao, RR; Zhang, R; Zheng, QD | 1 |
| Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG | 1 |
1 review(s) available for sorafenib and vitamin k 1
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for sorafenib and vitamin k 1
| Article | Year |
|---|---|
Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; BH3 Interacting Domain Death Agonist Protein; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fas Ligand Protein; Fas-Associated Death Domain Protein; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-jun; Pyridines; raf Kinases; Sorafenib; Vitamin K 1 | 2010 |
c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclic AMP-Dependent Protein Kinases; Diethylnitrosamine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Liver Neoplasms, Experimental; MAP Kinase Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-raf; Pyridines; Rats; Rats, Inbred F344; Signal Transduction; Sorafenib; Vitamin K 1 | 2011 |
Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Glioma; Humans; Immunoenzyme Techniques; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; raf Kinases; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Vitamin K 1; Vitamins | 2012 |
Synergistic Combination for Chemoprevention of Hepatocellular Carcinoma: An In Silico and In Vitro Approach.
Topics: Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Chalcone; Chemoprevention; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Docking Simulation; Niacinamide; Oxidative Stress; Phenylurea Compounds; Protein Interaction Maps; Sorafenib; Vitamin K 1 | 2017 |
Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Disease Progression; Enzyme Activation; Extracellular Matrix; Extracellular Signal-Regulated MAP Kinases; Humans; Hyperthermia, Induced; Liver Neoplasms, Experimental; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm, Residual; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vitamin K 1; Xenograft Model Antitumor Assays | 2017 |
Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
Topics: Actin Cytoskeleton; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Insulin-Like Growth Factor I; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Sorafenib; Vitamin K 1 | 2018 |